Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab-based tolerance induction in deceased donor liver transplantation
2023-508397-29-00Phase 2Suspended
- Sponsor
- ITB-MED
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siplizumab in Hepatic transplant rejection (LTR), sponsored by ITB-MED. Primary endpoint: Immunosuppression-free survival at Month 30. Started Jul 2024; status: suspended.
02
Drugs
siplizumab
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2023-508397-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508397-29-00.